Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Athira Pharma
Biotech
Athira's phase 2/3 Alzheimer's trial falls short, sinking stock
Fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up Athira’s stock price.
Nick Paul Taylor
Sep 4, 2024 6:52am
Athira's ALS drug boosts survival, slows motor decline in mice
Feb 12, 2024 1:35am
Ex-Celgene CEO takes the top job at TORL—Chutes & Ladders
Jan 12, 2024 9:30am
Athira’s losing streak continues with ph. 2 failure in dementia
Dec 12, 2023 9:25am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am
Athira fails in Alzheimer's, piling on pain before phase 3 data
Jun 22, 2022 7:06am